- Also known as
- CJC-1295 DAC · CJC 1295 with drug affinity complex · DAC:GRF · long-acting GHRH analogue
- Class
- Long-acting growth hormone-releasing hormone (GHRH) analogue
- Form
- Lyophilised powder in 5 mg and 10 mg vials
- Sizes
- 5 mg · 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 5 mg: 2 mL · 10 mg: 2 mL
What is CJC-1295 with DAC?
CJC-1295 with DAC is a long-acting growth hormone-releasing hormone (GHRH) analogue, and that classification is where the published work starts. Published work on it is in human, mouse and horse. The name covers the same material written several ways in the literature, including CJC-1295 DAC, CJC 1295 with drug affinity complex and DAC:GRF. Its sequence is recorded as Tetrasubstituted hGRF(1-29) with an added N-epsilon-3-maleimidopropionamide lysine at the C-terminus; about 30 residues.. One of the 6 studies listed below is a controlled trial in people. It is stocked here as lyophilised powder in 5 mg and 10 mg vials, for laboratory work only. Nothing here is a medicine; it is not for human or veterinary use.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Teichman SL et al.2006 · J Clin Endocrinol Metab · PMID 16352683 | Human, two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21-61 (n not stated in the abstract) | Four ascending single s.c. doses, then two or three weekly or fortnightly doses; 30 and 60 micrograms/kg named as better tolerated | 28 and 49 days | One injection raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9-11 days, with a half-life of 5.8-8.1 days. After multiple doses IGF-I stayed above baseline for up to 28 days, and no serious adverse reactions were reported. |
| Ionescu M et al.2006 · J Clin Endocrinol Metab · PMID 17018654 | Human, healthy men aged 20-40 (n not stated in the abstract) | 60 or 90 micrograms/kg, single injection | Overnight sampling before and 1 week after injection | GH secretion rose while pulse frequency and size were unchanged. Trough GH rose 7.5-fold, mean GH 46% and IGF-I 45%, with no difference between the two doses. |
| Sackmann-Sala L et al.2009 · Growth Horm IGF Res · PMID 19386527 | Human, healthy young men (n=11), serum proteomics | Not stated in the abstract | Sera before and 1 week after injection | Two protein spots fell (an apolipoprotein A1 isoform and a transthyretin isoform) and three rose, including beta-haemoglobin and albumin fragments. One spot varied linearly with IGF-1, and the authors propose these as possible biomarkers of GH or IGF-1 action. |
| Jetté L et al.2005 · Endocrinology · PMID 15817669 | Rat (Sprague Dawley) and cultured rat anterior pituitary cells | Not stated in the abstract (s.c.) | Plasma followed beyond 72 h | Albumin conjugates resisted DPP-IV breakdown and stayed active on pituitary cells. CJC-1295 gave a 4-fold larger GH area under the curve over 2 h than hGRF(1-29), bound to albumin within 15 min and was still in plasma beyond 72 h. |
| Alba M et al.2006 · Am J Physiol Endocrinol Metab · PMID 16822960 | Mouse, GHRH knockout (from 1 week of age) | 2 micrograms | 5 weeks, every 24, 48 or 72 h | Daily dosing gave normal body weight and length. Dosing every 48 or 72 h improved growth over placebo without normalising it, and treatment raised pituitary RNA and GH mRNA, with signs of somatotroph proliferation. |
| Timms M et al.2019 · Drug Test Anal · PMID 30489688 | Horse (thoroughbred), assay development and validation | Not stated in the abstract | Not stated in the abstract | An immuno-PCR assay detected the CJC-1295-protein conjugate down to 0.8 pg/mL, with a 50 pg/mL screening threshold in equine plasma. Albumin binding hides the peptide from standard mass-spectrometry peptide screens. |
What these studies don't show: The controlled evidence is real but covers a specific setting. Trial populations are selected, endpoints are often surrogate measures rather than outcomes, and follow-up rarely runs long. None of it establishes safety outside the conditions each trial ran under. Knowing the vial holds what the label says is not the same as knowing the compound does anything.
Every study links to its PubMed record. See all CJC-1295 with DAC studies in the research library →
CJC-1295 with DAC price in Canada: 5mg and 10mg vials
Buy CJC-1295 with DAC in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 5 mg | $52.00 | $10.40/mg |
| 10 mg | $72.50 | $7.25/mg |
Starter kit
Is CJC-1295 with DAC available in Canada?
CJC-1295 with DAC does not appear in the Drug Product Database as an authorized product. Health Canada has made no finding about it, because it has never been submitted for one. It is stocked here as laboratory research material and for no use in a person or an animal. How Health Canada treats research peptides →
Side effects reported in studies
Each statement is tied to the study that reported it. Any tolerability finding below is quoted from the study that reported it. Human work of this size does not establish a safety profile.
CJC-1295 with DAC FAQ
What is CJC-1295 with DAC?
CJC-1295 with DAC is a long-acting growth hormone-releasing hormone (GHRH) analogue. The published work on it is in human, mouse and horse. Borealis Peptides supplies it as lyophilised powder in 5 mg and 10 mg vials for in-vitro laboratory research. It is not authorized as a medicine and is not for use in any living subject. Every reference here is listed with the model it ran in and the finding as published.
Where can I buy CJC-1295 with DAC in Canada?
Borealis Peptides ships CJC-1295 with DAC from Canadian stock to research and business addresses in Canada. It is held in 5 mg and 10 mg vials. Every batch is tested by HPLC and the certificate names the batch in your vial. Orders are accepted for laboratory research only.
Is CJC-1295 with DAC legal in Canada?
CJC-1295 with DAC does not appear in the Drug Product Database as an authorized product. Health Canada has made no finding about it, because it has never been submitted for one. It is stocked here as laboratory research material and for no use in a person or an animal. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission.
How much CJC-1295 with DAC should I use?
We do not answer dosing questions. CJC-1295 with DAC is not supplied for use in a person or an animal, so there is no dose to describe. What this page carries is the amount each cited study used and the model it used it in, reproduced as the authors published it.
What human evidence is there for CJC-1295 with DAC?
Of the 6 studies cited, one is a controlled trial in people and the rest are animal or cell work. Each row names its model, the amount used and what the authors reported, so the weight of each study can be judged directly rather than through a summary.
Does CJC-1295 with DAC need refrigeration?
Storage for the sealed vial is −20 °C, away from light and moisture. In solution it is kept at 2–8 °C. Because the dry form is stable at room temperature, shipping needs no cold chain; refrigerate it when it arrives. Repeated freeze-thaw cycles and light exposure are the real risks, not the shipping.
How is the purity of CJC-1295 with DAC confirmed?
Identity and purity are confirmed by HPLC for each batch, not once per product. The certificate names the batch it belongs to, and that batch number is on the vial, so a result can be traced back to the exact material that produced it. Ask with your order number and we send it.
How does CJC-1295 with DAC compare with CJC-1295 (no DAC) and Ipamorelin?
They are different compounds with different published records, and this site does not rank them. CJC-1295 (no DAC) and Ipamorelin have 6 cited studies and 8 cited studies on their page against 6 here. Set the two evidence tables side by side and the difference is visible directly.
Why is CJC-1295 with DAC named in a Health Canada advisory?
Because it was among the peptides seized from sellers offering unauthorized injectable products online. The advisory concerns material sold for people to inject without authorization. Borealis Peptides supplies research material for laboratory use and sells nothing for injection or for any use in a person, which is the line that advisory draws.
Compare with
Related compounds
CJC-1295 (no DAC)
Growth hormone-releasing hormone (GHRH) analogue
Add 2 more to save 4%
Ipamorelin
Growth hormone secretagogue (ghrelin receptor agonist)
Add 2 more to save 4%
Tesamorelin
Growth hormone-releasing hormone (GHRH) analogue
Add 2 more to save 4%
